xCellSense™

What is xCellSense™?

xCellSense™ utilizes live cancer cells from AML and ALL patients to analyze drug response across up to 21 chemotherapeutic agents. By providing risk stratification for specific agents and predicting Minimal Residual Disease (MRD), it supports clinicians in selecting optimal treatment regimens.

Acute myeloid Leukemia (AML)

Acute lymphomablastic leukemia (ALL)

Our Technology

Proprietary Culture Technology: IMV-8

A specialized ex vivo culture medium that maintains high cell viability, enabling drug response evaluation under conditions that closely mimic the patient's in vivo tumor microenvironment.

Quantitative Drug Response Analysis

Dose-response curves are used to calculate IC₅₀, AUC, and Eₘₐₓ. Notably, Eₘₐₓ shows a high correlation with patient survival outcomes.

High-Throughput Drug Sensitivity Profiling

Fast, precise drug sensitivity analysis technology enabling testing acrss a wide concentration range (nM to μM).

Turnaround Time: 7 Days

Results delivered within 7 days, providing personalized treatment insights optimized for the patient's condition and characteristics.

Drug Sensitivity Analysis Results

Quantitative assessment of patient-derived cancer cell response to individual chemotherapeutic agents
Key pharmacodynamic parameters — IC₅₀, AUC, and Eₘₐₓ — derived from dose-response curves.
Published research confirms Eₘₐₓ as a clinically meaningful biomarker strongly associated with overall survival (Park et al, 2023)

Sample Drug Sensitivity Analysis Results ^{a) b)}

Sample Result for AML drug sensitivity test

AML : Acute Myeloid Leukemia

Kaplan-Meier survival curve stratification by drug sensitivity response for each treatment regimen
Quantitative risk stratification into high- and low-risk groups based on ex vivo drug sensitivity data

Venetoclax (VEN) + Hypomethylating agent (Azacitidine, Decitabine)
Cytarabine (AraC) + Anthracycline

Hazard ratio: A measure comparing relative risk of mortality between groups. Values >1 indicate that the high-risk group has a greater hazard of death compared to the low-risk group.
Log-rank p value: Statistical test comparing survival distributions between two groups. p < 0.05 indicates a statistically significant difference in survival between the groups.
Confidence intervals: 95% CI displayed as shaded regions on survival curves.

ALL : Acute Lymphocytic Leukemia

Prediction of relapse risk and post-treatment Minimal Residual Disease (MRD) status based on ex vivo drug sensitivity profiling
Published data demonstrate that Eₘₐₓ and Dₘₐₓ are significantly associated with early disease progression and MRD status (Park et al., 2025)

재발 혹은 사망한 환자들(왼쪽)과 그렇지 않은 환자들(오른쪽)의 항암제 감수성을 비교하였을 때, 재발한 환자들의 감수성이 더 높았습니다. 이를 바탕으로 본 환자분의 재발 및 사망 가능성을 예측하였습니다.

치료 후 MRD+로 판별된 환자분들(왼쪽)은 MRD- 환자분들(오른쪽)에 비해 항암제 감수성이 낮았습니다(왼쪽 그래프). 이를 바탕으로 본 환자분의 MRD 결과를 예측하였습니다. 참고로 감수성을 바탕으로 MRD+로 예측된 환자 분들은MRD-로 예측된 환자분들 보다 overall survival이 유의미하게 짧았습니다(Hazard Ratio of 3.1).

MRD: Residual cancer cells that may persist in the patient following treatment, detectable below the threshold of conventional morphology
Hazard ratio: A metric comparing relative mortality risk between patient subgroups. Values >1 indicate elevated risk in the high-sensitivity group
P value: Statistical significance metric for comparing survival distributions between groups. p < 0.05 indicates a statistically significant difference. Calculated using the log-rank method in this report
Confidence intervals: 95% CI displayed as shaded regions on survival curves.